RT Journal Article
SR Electronic
T1 Sex-based clinical and immunological differences in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.29.20126201
DO 10.1101/2020.08.29.20126201
A1 Li, Kening
A1 Huang, Bin
A1 Cai, Yun
A1 Wang, Zhihua
A1 Li, Lu
A1 Wu, Lingxiang
A1 Zhu, Mengyan
A1 Li, Jie
A1 Wang, Ziyu
A1 Wu, Min
A1 Li, Wanlin
A1 Wu, Wei
A1 Zhang, Lishen
A1 Xia, Xinyi
A1 Wang, Shukui
A1 Wang, Qianghu
YR 2020
UL http://medrxiv.org/content/early/2020/09/01/2020.08.29.20126201.abstract
AB Background Males and females differ in their immunological responses to foreign pathogens. However, most of the current COVID-19 clinical practices and trials do not take sex as consideration.Methods We performed an unbiased sex-based comparative analysis for the clinical outcomes, peripheral immune cells, and SARS-CoV-2 specific antibody levels of 1,558 males and 1,499 females COVID-19 patients from a single center. The lymphocyte subgroups were measured by Flow cytometry. Total antibody, Spike protein (S)-, receptor binding domain (RBD)-, and nucleoprotein (N)-specific IgM and IgG levels were measured by chemiluminescence.Results We found that the mortality and ICU admission rates were approximately 2-fold higher in males than that in females (P<0.005). Survival analysis revealed that sex is an independent prognostic factor for COVID-19 (Hazard ratio=2.2, P=0.003). The concentration of inflammatory factors in peripheral blood was significantly higher in males. Besides, the renal and hepatic abnormality induced by COVID-19 was more common in males during the hospitalization. The analysis of lymphocyte subsets revealed that the percentage of CD19+ B cell and CD4+ T cell was significantly higher in females (P<0.001) during hospitalization, indicating the stronger humoral immunity in females than males. Notably, the protective IgG sharply increased and reached a peak in the fourth week after symptom onset in females, while gradually increased and reached a peak in the seventh week in males.Conclusions The unfavorable prognosis of male COVID-19 patients may result from the weak humoral immunity and indolent antibody responses during SARS-CoV-2 infection and recovery. Early medical intervention and close monitoring are important, especially for male COVID-19 patients. Hormonal or convalescent plasma therapy may help improve the immunity of males to fight against SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Natural Science Foundation of China (Grant Nos. 81572893, 81972358, 81959113), Key Foundation of Wuhan Huoshenshan Hospital (Grant No. 2020[18]), Key Research& Development Program of Jiangsu Province (Grant Nos. BE2017733, BE2018713), Medical Innovation Project of Logistics Service (Grant No. 18JS005), Basic Research Program of Jiangsu Province (Grant No. BK20180036).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Medical Ethical Committee of Wuhan Huoshenshan Hospital (HSSLL011), and the Ethical Committee of Nanjing Medical University (2020-511).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request to the corresponding author